Wednesday, February 10, 2010, 1:53PM AEST - The Australian Stockmarket closes in 2 hours and 12 minutes.
To create a watchlist or portfolio of shares, Register

Halozyme Therapeutics, Inc. (HALO)

8:00AM AEST: 5.49 USD  Up 0.09 (1.67%)  
 MORE ON HALO 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 Halozyme Therapeutics, Inc. (NGM:HALO) Delayed quote dataEdit
Last Trade:5.49 USD
Trade Time: 8:00AM AEST
Change:Up 0.09 (1.67%)
Prev Close:5.40
Open:5.45
Bid:5.24 x 2000
Ask:7.86 x 2000
1y Target Est:11.33
Day's Range:5.22 - 5.52
52wk Range:3.93 - 8.09
Volume:423,018
Avg Vol (3m):391,400
Market Cap:503.14M
P/E (ttm):N/A
EPS (ttm):-0.74
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add HALO to Portfolio   Download Data

 HEADLINES 
HALOZYME THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online (Wed 12:30AM)
[video] Trading Smallcap Biotech
at TheStreet.com (Tue, Feb 2)
Halozyme signs research contract with BioAtla
AP (Wed, Jan 20)
Halozyme Announces Research Alliance with BioAtla for Conditionally Active Biologics
Business Wire (Tue, Jan 19)
HALOZYME THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure
EDGAR Online (Tue, Jan 12)
Halozyme to Present at J.P. Morgan Healthcare Conference on January 13
Business Wire (Wed, Jan 6)
Halozyme, Beazer: Early Volume Plays
at TheStreet.com (Wed, Jan 6)
HALOZYME THERAPEUTICS INC Financials
EDGAR Online Financials (Thu, Nov 12)
Halozyme Earnings Call scheduled for 11:00 am ET today
CCBN (Sat, Nov 7)
HALOZYME THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
EDGAR Online (Sat, Nov 7)
More Headlines for HALO...

 ANALYST 
EPS Est (next year) (Dec-09) :-0.70
EPS Est (in 2 years) (Dec-10) :-0.64
Avg Rec (current)*:1.8
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Halozyme Therapeutics, Inc., a biopharmaceutical company, develops and commercializes products targeting the extracellular matrix for the endocrinology, oncology, dermatology, and drug delivery markets.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices